Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Coordinate your semaglutide dose with other weekly activities you never miss, such as a work meeting or religious service
Ro taps Serena to Banish GLP-1 Stigmas After announcing tennis legend Serena Williams as a brand ambassador last August, direct-to-consumer healthcare company Rowhich sells GLP-1 medications including Ozempic, Wegovy, and Zepboundtapped the athlete to front its Healthier on Ro Super Bowl in-game ad
News provided by Novo Nordisk Jul 01, 2026, 07:00 ET Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events including death, heart attack, or stroke in adults with obesity and heart disease a claim only Wegovy can make Since launching in January 2026, Wegovy pill has reached 3 million prescriptions * Medicare GLP-1 Bridge participation now expands patient access to authentic, FDA-approved Wegovy , including the Wegovy pill PLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity
Potential reasons why semaglutide could be banned in the future: If studies show it gives a significant competitive advantage If athletes start using it solely for weight cutting rather than for a medical reason If it is found to have serious health risks when used in sports However, for now, semaglutide remains legal for athletes to use
